Sodium-glucose Transporter 2 Inhibitors
7
1
2
4
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
0.0%
0 terminated out of 7 trials
100.0%
+13.5% vs benchmark
71%
5 trials in Phase 3/4
25%
1 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (7)
SGLT2i Safety and Efficacy on Kidney Allograft Function in Non-diabetic Kidney Transplant Recipients
Acute Effects of SGLT2 Inhibitor on Kidney Allograft Oxygen Tension
Effect of Sodium-glucose Cotransporter-2 Inhibitor in Cellular Senescence in Patients With Cardiovascular Diseases or Type 2 Diabetes
Effect of Dapagliflozin on Body Weight in Overweight Women Consuming Different Proportions of Carbohydrate Diet.
Clinical Value of Adding Dapagliflozin in Patients With Nephrotic Syndrome
Empagliflozin in Diuretic Refractory Ascites
Sodium-glucose Co Transporter 2 (sGLT2) Inhibitor and Endogenous Ketone Production